Submit regulatory applications for lebrikizumab and mirikizumab
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Feb 2022
- Due
- 31 Dec 2022
- Delivered
- by 31 Dec 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“positive Phase 3 readouts for lebrikizumab for moderate-to-severe atopic dermatitis and mirikizumab for moderately-to-severely active ulcerative colitis that support regulatory submissions in 2022.”
What we found
Evidence strength A What the grades mean
Eli Lilly confirmed in SEC filings that regulatory submissions for both lebrikizumab and mirikizumab were completed in the U.S. and Europe during 2022.
-
A ELI Lilly & Co 10-K filed 2023-02-22
“Lebrikizumab(1)Atopic dermatitisSubmitted Submitted in the U.S. and Europe in 2022. Phase III trials are ongoing. MirikizumabUlcerative colitisSubmitted Submitted in the U.S., Europe, and Japan in 2022.” ✓ confirmed on the page
Market reaction: the shares moved -1.1% against the S&P 500 over the three sessions around the disclosure (21 Feb 2023 to 24 Feb 2023). What this measures
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- Submit
- Deliverable
- Regulatory submissions for lebrikizumab and mirikizumab
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you ELI Lilly & Co? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-LLY-004343 · Corrections policy